Clinical Trial Update: Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating empagliflozin for severe congenital neutropenia due to G6PC3 deficiency has completed, per the NIAID-sponsored study NCT0507…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Neutropenia Due to G6pc3 Deficiency
• Crohn Disease
• Inflammatory Bowel Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Crohn's Disease, Glycogen Metabolism | Phase 1 | Status: COMPLETED